Awardee OrganizationCOLUMBIA UNIVERSITY HEALTH SCIENCES
Description
Abstract Text
Accurate diagnosis is essential for proper medical treatment. Often this is confounded by the lack of or
limitation of informative diagnostic assays and tools. Infectious agents rarely found in a given community or
country commonly are not screened for as multiple single diagnostic assays are cost-prohibitive and tests for
the most likely agent is deemed warranted. Yet it is increasingly clear that as infectious agents appear in ,
new geographic regions and contexts, the medical and public heath communities must improve and
modernize the methodologies they utilize. The Center for Research in Diagnostics and Discovery aims to
develop, validate and implement multiplex platforms and predictive strategies that will advance detection of
novel pathogens, identify host factors that influence susceptibility of disease and predict effectiveness of
drugs and vaccines. We will bring together researchers in the fields of molecular biology, systems biology,
genetics, and bioengineering. We will also bring together members of the public health communities and
conservation biologists. Together, the investigators in the Center for Research in Diagnostics and Discovery
will advance knowledge and platforms for the detection of agents that are either previously unidentified,
known causes of epidemics, or select agents by developing and utilizing systems that could be rapidly
redirected for pathogens of any type.
Public Health Relevance Statement
RELEVANCE (See instructions):
Diagnostic assays are the primary point for medical treatment. The assays used today by the medical
community do not provide the efficiency and multiplexing that are key to rapid diagnosis and accurate
treatment. The Center for Research in Diagnostics and Discovery will apply and develop modern state-of-the
art technologies for the creation of new tools that can be informative to the medical community.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
621889815
UEI
QHF5ZZ114M72
Project Start Date
07-March-2014
Project End Date
28-February-2019
Budget Start Date
01-March-2017
Budget End Date
28-February-2018
Project Funding Information for 2017
Total Funding
$6,626,745
Direct Costs
$5,003,604
Indirect Costs
$1,623,141
Year
Funding IC
FY Total Cost by IC
2017
National Institute of Allergy and Infectious Diseases
$6,626,745
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5U19AI109761-04
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5U19AI109761-04
Patents
No Patents information available for 5U19AI109761-04
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5U19AI109761-04
Clinical Studies
No Clinical Studies information available for 5U19AI109761-04
News and More
Related News Releases
No news release information available for 5U19AI109761-04
History
No Historical information available for 5U19AI109761-04
Similar Projects
No Similar Projects information available for 5U19AI109761-04